SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant Stake in Lexicon Pharmaceuticals

FMR LLC and its affiliates, along with Abigail P. Johnson, reported a continued beneficial ownership of 9.6% of Lexicon Pharmaceuticals Inc.'s common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Lexicon Pharmaceuticals Inc. common stock.
• As of March 31, 2025, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 34,543,197 shares.
• This represents 9.6% of the total outstanding common stock of Lexicon Pharmaceuticals Inc.
• FMR LLC holds sole voting power over 34,532,483 shares and sole dispositive power over 34,543,197 shares.
• Abigail P. Johnson holds sole dispositive power over 34,543,197 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC are identified as relevant entities within FMR LLC's structure that beneficially own shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Lexicon Pharmaceuticals Inc.'s future outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing is a routine disclosure of a significant ownership stake by a major institutional investor in a pharmaceutical company. It does not provide specific industry trends or competitive analysis, but it highlights continued institutional interest in the pharmaceutical sector, specifically Lexicon Pharmaceuticals Inc.

Stakeholder Impact

• This filing primarily impacts shareholders by disclosing a significant institutional ownership stake, which can influence market perception of the company's stability and investor confidence. No direct impact on employees, customers, suppliers, or creditors is detailed.

Key Dates

Keywords

Lexicon Pharmaceuticals Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals